SNU423_LIVER
HCC · Hepatocellular Carcinoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- HCC
- cancer_type_detailed
- Hepatocellular Carcinoma
- subtype
- —
- cancer_type
- HCC
- ccle_sample_id
- SNU423_LIVER
- synthetic_from_ccle
- true
- display_name
- SNU-423
- ccle_lineage
- liver
- ccle_lineage_subtype
- hepatocellular_carcinoma
- oncotree_code
- HCC
- cancer_type_detailed
- Hepatocellular Carcinoma
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.626
- HYPOXIA+0.495
- UV_RESPONSE_DN+0.324
- GLYCOLYSIS+0.235
- E2F_TARGETS+0.208
- TNFA_SIGNALING_VIA_NFKB+0.203
- MITOTIC_SPINDLE+0.200
- APICAL_JUNCTION+0.187
- TGF_BETA_SIGNALING+0.186
- G2M_CHECKPOINT+0.179
Top 10 suppressed
- CHOLESTEROL_HOMEOSTASIS-0.193
- OXIDATIVE_PHOSPHORYLATION-0.178
- ESTROGEN_RESPONSE_LATE-0.176
- KRAS_SIGNALING_DN-0.153
- PEROXISOME-0.148
- BILE_ACID_METABOLISM-0.146
- SPERMATOGENESIS-0.129
- INTERFERON_ALPHA_RESPONSE-0.098
- FATTY_ACID_METABOLISM-0.075
- ALLOGRAFT_REJECTION-0.074
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SNU387_LIVER | HCC | — | 0.718 |
| 2 | SRR12475162 | — | — | 0.709 |
| 3 | SRR25617936 | — | E | 0.689 |
| 4 | 247323b2-dc45-427e-bc41-c33f2fbbe77b | — | — | 0.688 |
| 5 | TCGA-BH-A0AV-01A-31R-A115-07 | — | E | 0.687 |
| 6 | TCGA-CV-6950-01A-11R-1915-07 | — | — | 0.663 |
| 7 | SRR934963 | — | — | 0.662 |
| 8 | SRR2932813 | — | — | 0.662 |
| 9 | HLF_LIVER | HCC | — | 0.659 |
| 10 | SRR5903555 | — | cohortSQ1 | 0.655 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 29 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.626 | Inavolisib | — uncovered |
| HYPOXIA | 0.495 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.324 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.235 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.208 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.203 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.200 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.187 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.186 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.179 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.163 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.163 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.141 | Remibrutinib | — uncovered |
| MYC_TARGETS_V2 | 0.096 | Idelalisib | — uncovered |
| COAGULATION | 0.096 | Binimetinib | — uncovered |
| COMPLEMENT | 0.095 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.091 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.064 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.052 | Inavolisib | — uncovered |
| APOPTOSIS | 0.051 | Idelalisib | — uncovered |